| Customers: Shinmyung Mediyes Pharmaceuticals, Medicine, Healthcare Contractors: R-Pharm Project date: 2025/11
|
The pharmaceutical company R-Pharm plans to supply Korean insulin pumps to Russia and localize their production. The company received permission to import Will Care 2 branded pumps and the Will Lifeline VA infusion kit from the Korean company Shinmyung Mediyes. This was reported by two sources in the medical device market on November 3, 2025.
According to RBC, the localization of the production of these pumps is planned no earlier than 2026. In September 2025, R-Pharm acquired a subsidiary of R-Diabetron, its main activity is the production of medical instruments and equipment. The pharmaceutical company owns 80% in the authorized capital of R-diabetron, the remaining 20% belongs to the medical device supplier Commed Cardio.
The representative of R-Pharm noted that the company and Commed Cardio are developing a joint venture R-diabetron in order to increase the availability of modern high-tech drug delivery systems. It is planned to supply partner products, localization subject to the requirements of Russian regulation and quality standards, the creation of its own production within the framework of import substitution of socially significant products.
An insulin pump is a device that supplies insulin to the patient's body, mimicking the work of a healthy pancreas. Such devices are designed for people with diabetes. In Russia, 5.6 million people were registered with such a diagnosis. Insulin with pumps is injected around the clock and does not require multiple daily injections.
According to the state corporation Rostec, about 50 thousand people in the country use insulin pumps. Government purchases of insulin pumps and consumables are growing. According to the results of all 2024, the state purchased such products for ₽16,6 billion, and for ten months of 2025 - already for ₽18,2 billion.
Most of the costs are pump consumables. ₽1,8 billion was spent on the pumps themselves in 2024, and ₽1,3 billion in 2025. The public procurement market for insulin pumps is completely occupied by imported products.[1]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |